338 completed, 64 terminated, 52 unknown, 31 active not recruiting. 325 Phase 2, 158 Phase 1, 84 Phase 3, 11 Not applicable, 1 Early Phase 1.
Follow Gemcitabine Hydrochloride: new trials by email Literature Review of Gemcitabine Hydrochloride trials Research Report on Gemcitabine Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms Ablation Therapy, Biospecimen Collection, Computed Tomography - Pancreatic Cystic Neoplasm | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2026-05-12 | 2026-05-29 |
| A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer FG-M108, nab paclitaxel, Gemcitabine (GEM) - Pancreatic Cancer | Phase 3 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 524 | 2026-02-28 | 2026-02-04 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 140 | 2025-10-20 | 2026-10-19 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer gemcitabine hydrochloride, Cisplatin, Nab-paclitaxel - Gallbladder Cancer Unresectable | Phase 2 | Recruiting | Fudan University | 33 | 2024-10-24 | 2026-05-14 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions Gemcitabine, Nab-Sirolimus - Leiomyosarcoma, Soft-tissue Sarcomas | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2024-08-14 | 2026-09-25 |
| Clinical Study Evaluating the Effect of Losartan Losartan 50mg Tab - Pancreatic Cancer | Not applicable | Completed | Tanta University | 90 | 2024-07-20 | 2026-10-05 |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 200 | 2024-06-12 | 2025-08-15 |
| Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial Cisplatin, Gemcitabine Hydrochloride, Infigratinib Phosphate - Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 2 | Withdrawn | Emory University | 2024-03-01 | 2023-12-26 | |
| A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer Gemcitabine, Nab-paclitaxel, YL-13027 - Metastatic Pancreatic Cancer | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2024-01-22 | 2025-12-08 |
| Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer Ascorbate, Nab paclitaxel, Gemcitabine - Metastatic Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 100 | 2023-08-20 | 2025-08-07 |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study Toripalimab, Lenvatinib mesylate capsules, Placebo IV - Intrahepatic Cholangiocarcinoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 480 | 2023-06-19 | 2025-04-23 |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 | Suspended | National Cancer Institute (NCI) | 43 | 2023-06-12 | 2026-09-09 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer Atezolizumab, Bevacizumab, Biospecimen Collection - Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2022-12-07 | 2026-08-13 |
| A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. Gemcitabine, Nab paclitaxel, IM156 - Pancreas Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 19 | 2022-10-21 | 2026-10-07 |
| A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection - Malignant Tumors | Phase 1 / Phase 2 | Completed | Nanjing Leads Biolabs Co.,Ltd | 98 | 2022-09-01 | 2026-04-01 |
| Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Terminated | SWOG Cancer Research Network | 6 | 2022-08-10 | 2024-12-30 |
Showing 20 of 527. Sign in to see all of them.
Pancreatic Neoplasms (152) · Carcinoma, Non-Small-Cell Lung (83) · Lung Neoplasms (75) · Urinary Bladder Neoplasms (51) · Ovarian Neoplasms (31) · Lymphoma (30) · Breast Neoplasms (27) · Hodgkin Disease (26) · Adenocarcinoma of Lung (23) · Fallopian Tube Neoplasms (20) · Urethral Neoplasms (20) · Carcinoma, Ovarian Epithelial (19) · Gallbladder Neoplasms (19) · Lymphoma, Large B-Cell, Diffuse (17) · Bile Duct Neoplasms (16)
National Cancer Institute (NCI) (79) · M.D. Anderson Cancer Center (42) · Alliance for Clinical Trials in Oncology (37) · SWOG Cancer Research Network (18) · Gynecologic Oncology Group (16) · Roswell Park Cancer Institute (14) · Eastern Cooperative Oncology Group (12) · European Organisation for Research and Treatment of Cancer - EORTC (12) · Mayo Clinic (12) · Memorial Sloan Kettering Cancer Center (12) · City of Hope Medical Center (10) · GERCOR - Multidisciplinary Oncology Cooperative Group (10) · Barbara Ann Karmanos Cancer Institute (8) · NCIC Clinical Trials Group (8) · Case Comprehensive Cancer Center (7)
United States (402) · Canada (49) · France (31) · United Kingdom (28) · Puerto Rico (15) · Belgium (14) · Australia (13) · Italy (13) · Netherlands (13) · China (12) · Germany (12) · Switzerland (9) · Israel (8) · South Korea (7) · Singapore (6)
Hedy Kindler (5) · Malcolm J. Moore, MD (5) · Steven R. Alberts, MD (5) · Yago Nieto, MD, PHD (5) · Arthur William Blackstock, MD (4) · Christophe Louvet, MD, PhD (4) · Philip A. Philip, MD, PhD, FRCP (4) · Al B. Benson, MD, FACP (3) · Alex A. Adjei, MD, PhD (3) · Alex Adjei (3) · Andrew Ko, MD (3) · Christopher H. Crane, MD (3) · Corey J. Langer, MD (3) · Dean F. Bajorin, MD (3)
PMID 33951890, PMID 37185961, PMID 10442378, PMID 11815964, PMID 11896099, PMID 11919245, PMID 12065559, PMID 12618501, PMID 12649105, PMID 12767086, PMID 12837810, PMID 12947059, PMID 14581415, PMID 14630682, PMID 14751144, PMID 14766260, PMID 14998842, PMID 15131031, PMID 15218298, PMID 15361643, PMID 15386331, PMID 15558814, PMID 15589587, PMID 15611509, PMID 15646530, PMID 15661234, PMID 15803016, PMID 15839957, PMID 15908661, PMID 15911238, PMID 15929131, PMID 16062075, PMID 16135464, PMID 16150481, PMID 16170174, PMID 16271750, PMID 16303865, PMID 16361622, PMID 16601427, PMID 16643994, PMID 16868545, PMID 16909426, PMID 16966687, PMID 16968876, PMID 16983112, PMID 17065590, PMID 17084621, PMID 17145828, PMID 17264337, PMID 17290059
U10CA032102 (17), U10CA031946 (15), U10CA027469 (10), P30CA022453 (9), P30CA043703 (9), U10CA180820 (9), P30CA015083 (8), U10CA180868 (7), P30CA036727 (6), P30CA072720 (6), U10CA180821 (6), P30CA033572 (5), U10CA021661 (5), 2005 (4), N01CM00038 (4)